Currently, lower-level 9p24.1 alterations and low PD-L1 expression on HRSCs, as well as negative MHC-II expression on HRSCs in patients with a short interval between ASCT and the PD-1-blocking therapy, are associated with worse PFS in patients with RR cHL. This evidence concerns the gene CD274 and classic Hodgkin lymphoma.